Dimebon (latrepirdine) is an investigational compound currently in Phase 3 development for the treatment of Alzheimer's disease (AD) and for Huntington's disease (HD).
In preclinical models of AD and HD explored thus far, dimebon (latrepirdine) has been shown to inhibit brain cell death, potentially by stabilizing and improving mitochondrial function in a way that prevents neuron death and dysfunction.
Other dimebon (latrepirdine) clinical trials
In a recent pivotal clinical trial of dimebon (latrepirdine) in patients with mild to moderate Alzheimer's disease, the following points were examined:
•
Cognition and memory
•
Activities of daily living
•
Overall clinical function
•
Behavioral problems
To learn about clinical trials examining the efficacy and safety of dimebon (latrepirdine), visit www.DimebonTrials.com
Learn more about dimebon (latrepirdine) at Medivation.com.
Dimebon is an interim name.
The Concert Study is a Phase 3 trial sponsored by Medivation, Inc, and Pfizer Inc.
